Bernstein says it "roughly" agrees with the consensus outlook on the next step in the saga involving Teva (TEVA), Mylan (MYL) and Perrigo (PRGO), i.e.it expects Teva to increase its bid for Mylan to $88-$90 and Mylan to raise its bid for Perrigo to $224-$235. The firm sees Mylan as the safest bet among the three stocks, as it believes that Teva's offer should be accepted, since it will be more lucrative for Mylan's shareholders than an acquisition of Perrigo, according to Bernstein. The firm sees Teva as the second best option for investors, as it believes that the stock will probably rise to $75 if the company does buy Mylan. However, the firm notes that Teva, unlike Mylan, does not have an immediate fallback option if its plan does not materialize. Bernstein keeps Outperform ratings on Teva and Mylan.